作者: Towia Aron Libermann , Yvonne Junker , Simon T. Dillon , Detlef Schuppan
DOI:
关键词:
摘要: The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, 0.19 (0.19), CMl, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or 0.53 (0.53). To this end, pharmaceutical compositions including neutralizing antibodies to 0.19, CM16, 0.53, food products containing reduced levels CMl 6, protein, use oral TLR4 inhibitors block effect said alpha-amylase inhibitors, assays for identifying content in products, and diagnosing subjects a disorder related responses.